Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 220

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 220
---
 prices that are based on inputs not quoted on active markets but corroborated by market data.                                    |
| Level 
 3     | - | Unobservable                                                                                                                     
 inputs reflecting the Company’s assumptions, consistent with reasonably available assumptions made by other market participants. 
 These valuations require significant judgment.                                                                                   |

The Company may choose to elect the FVO for certain eligible financial instruments, such as certain Promissory Notes, in order to simplify the accounting treatment. Items for which the FVO has been elected are presented at fair value in the Consolidated Balance Sheets and any change in fair value unrelated to credit risk is recorded in Other Expense, net in the Consolidated Statements of Operations and Comprehensive Loss. Changes in fair value related to credit risk are recognized in Other Comprehensive Loss. As a result of the completion of the IPO, all financial instruments for which the FVO was elected were extinguished. See Note 7 for more information on the extinguishment of the Promissory Notes.

F-15

The Company’s financial instruments recorded at fair value on a recurring basis at December 31, 2024, and December 31, 2023 include the derivative liability associated with the contingent milestone payment due to Knight upon a future sale of Arakoda™ or a Change of Control, which is carried at fair value based on Level 3 inputs. The Company uses a probability-weighted expected return method to determine the fair value of the contingent milestone payment using significant inputs such as the timing and probability of discrete potential exit scenarios, forward interest rate curves, and discount rates based on implied and market yields. See Note 8 for more information on Derivative Liabilities.

Liabilities measured at fair value at December 31, 2024 and 2023 are as follows:

|                        |     | December 31, 2024 |   |     |         |   |     |         |         |     |       |         |
|:-----------------------|:----|:------------------|:--|:----|:--------|:--|:----|:--------|--------:|:----|:------|--------:|
|                        |     | Level 1           |   |     | Level 2 |   |     | Level 3 |         |     | Total |         |
| Liabilities:           |     |                   |   |     |         |   |     |         |         |     |       |         |
| Derivative Liabilities |     | $                 | - |